PT-141
Also Known As: Bremelanotide, Vyleesi, PT 141, PT141, Melanocortin sexual peptide, MC4R agonist peptide, Libido peptide, Sexual arousal peptide, Cyclic lactam MSH analog, Melanocortin-4 receptor agonist, Hypoactive sexual desire peptide, HSDD treatment, Female sexual dysfunction peptide, Bremelanotide acetate, melanocortin agonist
PT-141 is a research-grade Cyclic heptapeptide melanocortin receptor agonist targeting MC4R studied in Sexual Health & Hormones research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Approved Drug - FDA and/or EMA approved with robust human trial data.
An approved desire-disorder peptide for premenopausal women, acting in the brain.
At A Glance
| Category | Sexual Health & Hormones |
|---|---|
| Compound Class | Cyclic heptapeptide melanocortin receptor agonist; Melanotan II analog without linear structure |
| Molecular Target | MC4R (melanocortin-4 receptor) in hypothalamus; dopaminergic sexual arousal pathway; also MC1R (minor) |
| Molecular Weight | 1025.18 Da |
| Amino Acid Sequence | Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH |
| CAS Number | 189691-06-3 |
| Half-Life | ~2.7 hours |
| WADA Status | not_listed |
| Evidence Tier | Approved Drug |
Mechanism Of Action
It bypasses the vascular system entirely and binds to melanocortin receptors in the brain (MC3R and MC4R), directly stimulating the central nervous system pathways responsible for sexual arousal.
Studied For
- Hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA approved)
- Erectile dysfunction research (historical)
- Female sexual arousal disorder
- Male sexual dysfunction research
- Libido enhancement
- Sexual arousal stimulation
- Melanocortin system sexual research
- Orgasmic dysfunction research
- Pornography-induced erectile dysfunction models
- Testosterone-independent sexual arousal
- CNS-mediated sexual response
- Female orgasm research
- libido
- erectile dysfunction
- ED
- female sexual arousal disorder
- aphrodisiac
- sexual dysfunction
Reported Research Findings
Phase 3 trials in premenopausal women with low sexual desire showed significant improvement versus placebo, with modest effect sizes.
Safety And Handling Notes
Nausea (the leading reason for discontinuation), flushing, headache, transient blood-pressure rise, and focal skin or gum darkening with repeated use.
Contraindicated in uncontrolled hypertension or known cardiovascular disease; approved only for premenopausal women, not for men or performance.
Regulatory Status
FDA-approved (Vyleesi, 2019) for premenopausal HSDD.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.